Stock Market Reviews

Read and share opinions on ANNX (Annexon, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy
  BRISBANE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it will host an in-person and virtual key opinion leader (KOL) event in New York on Wednesday, March 18, 2026, with presentations at 2:00 PM ET and a reception at 4:00 PM ET. To register, click here. The event will inc
  Feb 17, 2026
• Does Annexon’s EMA Filing For Tanruprubart Reshape The Bull Case For ANNX?
  Earlier this month, Annexon submitted a Marketing Authorization Application to the European Medicines Agency for tanruprubart to treat Guillain-Barre syndrome, supported by randomized studies showing rapid effects on neuroinflammation and disability measures. The filing, alongside plans for a U.S. Biologics License Application and broader FORWARD study, positions tanruprubart as a potential first-in-class option in a disease with no FDA-approved treatments. We’ll now examine how Annexon’s...
  Jan 20, 2026
• Assessing Annexon (ANNX) Valuation After EMA Filing For Tanruprubart In Guillain Barre Syndrome
  Annexon (ANNX) is back in focus after the company submitted a Marketing Authorization Application to the European Medicines Agency for tanruprubart in Guillain Barre syndrome, marking a key regulatory moment for this clinical program. See our latest analysis for Annexon. The MAA news arrives after a strong 90-day share price return of 92.09% and a 30-day share price return of 17.41%, pointing to building momentum despite a 1-day share price dip of 1.46% and mixed longer term total shareholder...
  Jan 18, 2026
• Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
  BRISBANE, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on January 9, 2026, in accordance with Nasdaq Listing Rule 5635
  Jan 16, 2026
• Annexon Maps “Pivotal” 2026 at JPM Conference: ANX007 Phase 3 GA Readout, ANX005 Filings Ahead
  Annexon (NASDAQ:ANNX) used its presentation at the 44th Annual J.P. Morgan Healthcare Conference to outline a set of late-stage and mid-stage milestones that CEO Doug Love described as setting up 2026 as a “pivotal year” for the company. Love highlighted two registration-stage programs—ANX007 in geo
  Jan 14, 2026
• Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026
  Tanruprubart MAA Filed with Potential to Be the First Targeted Fast-Acting Therapy for Guillain-Barré Syndrome (GBS); BLA Submission with U.S./European Data Planned in 2026 Vonaprument Pivotal Phase 3 Topline Data for Dry AMD with Geographic Atrophy (GA) on Track for Second Half of 2026 Evaluating Unprecedented Effect on Vision Protection Proof-of-Concept Data for ANX1502, the First Oral C1 Inhibitor for Autoimmune Disease, Expected in 2026 Strong Financial Position Funds Operations into Late 20
  Jan 12, 2026
• Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome
  Potential to Be the First Targeted Fast-Acting Therapy for GBS, Setting a New Standard of Care BLA Submission with U.S./European Data from FORWARD Trial Planned in 2026 BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced it has submitted a Marketing Authorization Application
  Jan 8, 2026
• Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
  BRISBANE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, president and chief executive officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 11:15 a.m. PST. A live webcast of the event can be accessed under
  Jan 7, 2026
• Here Are Tuesday’s Top Wall Street Analyst Research Calls: AMETEK, Coty, Janus Henderson, Levi Strauss, Pool Corporation, Southern Copper, and More
  Pre-Market Stock Futures: The futures are trading flat after a solid start to the shortened Christmas holiday week. All of the major indices finished the day higher, but with the big event just 48 hours away, you can bet the trading volume will fall off a cliff. Wednesday will be a day for the junior ... Here Are Tuesday’s Top Wall Street Analyst Research Calls: AMETEK, Coty, Janus Henderson, Levi Strauss, Pool Corporation, Southern Copper, and More
  Dec 23, 2025
• Clear Street Asserts Buy Rating on Annexon, Inc. (ANNX) amid Progress on Pipeline Development
  Annexon Inc. (NASDAQ:ANNX) is one of the best multibagger penny stocks to buy right now. On December 1, Clear Street initiated coverage of Annexon Inc. (NASDAQ:ANNX) with a Buy rating and a $17 price target. The positive stance is in response to the progress the company has made in developing complement inhibitors for inflammation-related diseases. […]
  Dec 18, 2025
• Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
  BRISBANE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on December 10, 2025, in accordance with Nasdaq Listing Rul
  Dec 17, 2025
• 3 High Growth Tech Stocks To Watch In The US Market
  As the U.S. market grapples with fluctuating indices and AI bubble concerns, the Dow Jones Industrial Average recently hit an all-time high before retreating, while tech-heavy stocks like those in the Nasdaq face pressure amid broader economic uncertainties. In this dynamic environment, identifying high-growth tech stocks involves looking for companies that demonstrate resilience and adaptability to market shifts, particularly those that can navigate technological advancements and investor...
  Dec 15, 2025
• With Annexon Up 14%, Insider Buyers Count Their Returns
  Last week, Annexon, Inc. ( NASDAQ:ANNX ) insiders, who had purchased shares in the previous 12 months were rewarded...
  Dec 11, 2025
• Analyst Confidence Strong in Annexon (ANNX) Amid Vonaprument Advancement
  Annexon, Inc. (NASDAQ:ANNX) is one of the 12 hot penny stocks to invest in right now. On November 19, 2025, The Fly reported that Wells Fargo increased its price target on Annexon, Inc. (NASDAQ:ANNX) from $14 to $27, while reiterating an “Overweight” rating. The investment firm’s price revision reflects its increased probability of success in the second […]
  Nov 29, 2025
• Exploring 3 High Growth Tech Stocks In The US Market
  The United States market has recently experienced mixed performances, with the Dow Jones Industrial Average declining for two consecutive days while technology shares have shown signs of rebounding. Amidst these fluctuations, investors are paying close attention to high-growth tech stocks, which can offer potential opportunities due to their innovative capabilities and adaptability in a rapidly evolving economic landscape.
  Nov 14, 2025
• Annexon Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million
  BRISBANE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announced the closing of its previously announced underwritten public offering of 29,423,075 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 4,326,922 additional shares of
  Nov 14, 2025
• Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants
  BRISBANE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announced the pricing of its previously announced underwritten public offering of 25,096,153 shares of its common stock at a price to the public of $2.60 per share and, in lieu of shares of common stock to certain investors,
  Nov 13, 2025
• Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
  BRISBANE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announced that it has commenced an underwritten public offering of $75 million of shares of its common stock or pre-funded warrants to purchase shares of its common stock in lieu thereof. All of the securities are being offered by Annex
  Nov 12, 2025
• Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
  Late-Stage Neuroinflammation Platform Advancing Global Registrational Programs in Guillain-Barré Syndrome (GBS) and Geographic Atrophy (GA) Current Tanruprubart GBS Dossier On Track for MAA Filing in January 2026; Potential to Be the First Approved Targeted and Fast-Acting Therapy for the Treatment of GBS; Continued FDA Discussions Regarding Generalizability Package in Support of BLA Filing Topline ARCHER II Pivotal Data for Vonaprument in Dry AMD with GA on Track for Second Half of 2026; Potent
  Nov 10, 2025
• Nuveen Expands Portfolio With Annexon, Inc. (ANNX) Acquisition
  Annexon, Inc. (NASDAQ:ANNX) is among the best fast money stocks to buy now. During the first quarter, Nuveen LLC acquired a new position in Annexon, Inc. (NASDAQ:ANNX) through the purchase of 23,491 shares of the company’s stock. According to a recent disclosure with the SEC, the global asset firm now owns 0.14% of the company, […]
  Sep 30, 2025

• ChartPilot

  Feb 17, 2026

  $ANNX Navigating the biotech maze is no easy feat, and the clock is ticking! Can this company make the breakthroughs needed, or will they fall short of expectations?

  Sell

• PortfolioFreak

  Feb 17, 2026

  $ANNX Emerging therapies are often met with skepticism, and this company is no exception. Its bold approach could either revolutionize treatment or lead to disappointment. The stakes are incredibly high, and the clock is ticking!

  Sell

• BearBreaker

  Feb 15, 2026

  $ANNX If innovation were a crime, they’d be innocent.

  Sell

• ShortRaid

  Feb 15, 2026

  $ANNX In the biopharmaceutical landscape, this company is making strides with its focus on unmet medical needs. Their research pipeline holds the potential for breakthroughs that could significantly impact patient care.

  Buy

• StockShotz

  Feb 14, 2026

  $ANNX If stocks were snacks, this one would definitely be the trendy avocado toast—everyone's talking about it!

  Buy

• EquityAssault

  Feb 14, 2026

  $ANNX Enough promises to fill a book, but where's the substance?

  Sell

• FinTechFrost

  Feb 13, 2026

  $ANNX If this stock were a superhero, it would be the one that shows up late but saves the day with style!

  Sell

• DividendVortex

  Feb 13, 2026

  $ANNX This biopharmaceutical firm is pioneering advancements in treating neurological conditions, demonstrating a strong pipeline that could lead to significant breakthroughs. Its research-focused approach may yield promising results for investors.

  Buy

• MarginMarauder

  Feb 12, 2026

  $ANNX The future looks bright for this one! I mean, who wouldn’t want a little sprinkle of innovation?

  Buy

• OptionCipher

  Feb 12, 2026

  $ANNX This one has potential lurking just beneath the surface, yet every tick could bring anxiety. Will it breakthrough or fizzle out? The suspense is nerve-wracking!

  Buy

• CapitalFrame

  Feb 12, 2026

  $ANNX The focus on groundbreaking therapies in the biotech industry is paramount. With promising clinical trial results, this company is well-poised to make a significant impact on healthcare solutions.

  Buy

• CandleCrusher

  Feb 12, 2026

  $ANNX With groundbreaking developments on the horizon, the stakes are sky-high for this firm. Will it transform lives or fade into obscurity? The pressure is on, and time is running out for something significant!

  Buy

• TradeRebel

  Feb 11, 2026

  $ANNX In a fast-evolving biotech world, every moment counts. Are they pioneering breakthroughs or just another name trying to keep up with the relentless pace of innovation?

  Buy

• TradeReckoner

  Feb 11, 2026

  $ANNX Investing here is like tossing money into a black hole.

  Sell

• ShortSqueezeX

  Feb 11, 2026

  $ANNX Think of this as the underdog in a sports movie—full of heart and fighting spirit, but you never know if it’ll win the big game!

  Buy

• BuyTheDipBro

  Feb 11, 2026

  $ANNX Chasing big dreams in biotech, keep your eyes peeled for moves!

  Buy

• MarginMythic

  Feb 9, 2026

  $ANNX With major catalysts on the horizon, this one is like a ticking time bomb! Will it explode with potential or fizzle out? Investors are on the edge of their seats!

  Buy

• ProfitLancer

  Feb 9, 2026

  $ANNX Another biotech that promises miracles but delivers nothing.

  Sell

• ShortSurge

  Feb 8, 2026

  $ANNX Focusing on novel therapeutic developments, this company is at the forefront of addressing unmet medical needs. Its research pipeline suggests a promising future for innovations in healthcare.

  Buy

• MarketSavage

  Feb 7, 2026

  $ANNX A great way to lose interest quickly.

  Sell

• CapitalNova

  Feb 6, 2026

  $ANNX This company is at the forefront of developing innovative therapies that target severe autoimmune diseases. Their commitment to scientific excellence and patient outcomes signals a bright future in the biopharmaceutical landscape.

  Buy

• ByteBull

  Feb 6, 2026

  $ANNX This one's like that elusive unicorn at a fair—rare, mysterious, and everyone wants a peek!

  Buy

• OptionRogue

  Feb 6, 2026

  $ANNX With innovative research at the forefront of its operations, this biotech firm shows promise in addressing unmet medical needs. Their robust pipeline could lead to significant advancements in treatment options, appealing to investors interested in the health sector.

  Buy

• StonkKnight

  Feb 6, 2026

  $ANNX Potential’s brewing, but it’s still a wild card.

  Sell

• MarketMarauder

  Feb 5, 2026

  $ANNX Their promise is as empty as their stock price.

  Sell

• PortfolioPunk

  Feb 5, 2026

  $ANNX They're not just Annexed; they're practically lost in the void.

  Sell

• MarketGlitch

  Feb 4, 2026

  $ANNX With groundbreaking science on the table, the stakes are incredibly high. It's a race against time, and every misstep could change everything!

  Buy

• MemeInvestor

  Feb 4, 2026

  $ANNX Feels like that genius kid who cracked the code to your favorite game. It’s got potential written all over it!

  Buy

• DividendFrame

  Feb 4, 2026

  $ANNX Focused on pioneering treatments for neurodegenerative diseases, this company is at the forefront of addressing significant unmet medical needs. Their innovative approach could lead to breakthroughs that transform patient outcomes.

  Buy

• BullishShade

  Feb 4, 2026

  $ANNX This company is a key player in the biopharmaceutical industry, focusing on innovative treatments for neurodegenerative diseases. Their commitment to research and development positions them well for potential breakthroughs that could significantly impact patient care.

  Buy

• MarginMythic

  Feb 3, 2026

  $ANNX This biotech company looks promising, but the competition is fierce and the stakes are high. Every day feels like a nail-biting cliffhanger, and you can’t help but wonder if they’ll beat the odds!

  Buy

• TickerTakedown

  Feb 3, 2026

  $ANNX This company's got more potential than my New Year's resolutions—let's hope they stick around longer than January!

  Buy

• ShortAndProud

  Feb 3, 2026

  $ANNX They’re steppin' up their game, keep your eye on this player!

  Buy

• RiskProtocol

  Feb 2, 2026

  $ANNX Hope and anxiety intertwine as they face pivotal trials. Every update leaves you holding your breath—will they break through barriers or face setbacks?

  Sell

• ProfitLancer

  Feb 2, 2026

  $ANNX Innovation or just another excuse for failure?

  Sell

• VolatilityViper

  Feb 1, 2026

  $ANNX Seems like a medical miracle that missed the shot.

  Sell

• OptionSpectre

  Feb 1, 2026

  $ANNX More hype than substance; welcome to the letdown.

  Sell

• CashCombo

  Feb 1, 2026

  $ANNX This company is on a mission to stop diseases in their tracks—like a superhero, but for cells. Capes are optional!

  Buy

• StockSpecter

  Feb 1, 2026

  $ANNX Their research is about as promising as a soggy sandwich.

  Sell

• AlphaStriker

  Feb 1, 2026

  $ANNX This one's not just annexing territory; it's annexing your confidence.

  Sell

• TheQuantEdge

  Jan 31, 2026

  $ANNX In the race for breakthrough treatments, every second is monumental! The journey from discovery to delivery is fraught with uncertainty, and the stakes couldn't be higher.

  Buy

• PortfolioPunk

  Jan 31, 2026

  $ANNX The future looks dim, like a bulb in the attic that's never been changed.

  Sell

• RiskAssassin

  Jan 31, 2026

  $ANNX With clinical trials hanging in the balance, the suspense is palpable. One announcement could change everything, and investors are feeling the tension!

  Buy

• AlphaDruid

  Jan 30, 2026

  $ANNX Bullish cross on key indicators.

  Buy

• StonkDestroyer

  Jan 29, 2026

  $ANNX Chasing shadows instead of breakthroughs.

  Sell

• BagholderPrime

  Jan 29, 2026

  $ANNX This company's like that friend who always brings the snacks to the party – everyone just wants to hang out more!

  Buy

• CryptoCobra

  Jan 26, 2026

  $ANNX If this company were a superhero, it would definitely have a cape - saving the day one discovery at a time!

  Buy

• ShortCircuit

  Jan 26, 2026

  $ANNX Still waiting for the 'next big thing' to arrive.

  Sell

• LiquidLegend

  Jan 26, 2026

  $ANNX Think of them as the cool kids in science class—always coming up with the next big thing while looking effortlessly smart.

  Buy

• BearFighter

  Jan 26, 2026

  $ANNX Hoping for a miracle? Good luck with that.

  Sell

• RiskRaider

  Jan 25, 2026

  $ANNX This one sounds like it’s just here to keep the lights on.

  Sell

• OptionOutlaw

  Jan 24, 2026

  $ANNX Good luck standing out in a sea of mediocrity.

  Sell

• HedgeMeNot

  Jan 24, 2026

  $ANNX Battlin' big challenges, but the road's tough, ya dig?

  Sell

• TradePredator

  Jan 24, 2026

  $ANNX Looks like a science project gone wrong. Good luck with that.

  Sell

• ShortKingston

  Jan 24, 2026

  $ANNX Investing here feels like trying to find the last slice of pizza at a party. You're hopeful, but it's a bit of a gamble!

  Sell

• FiscalRiot

  Jan 23, 2026

  $ANNX This stock is hanging by a thread! Market whispers are growing louder. Is it enough to keep afloat, or is it time to brace for impact?

  Sell

• TheTradingVerse

  Jan 23, 2026

  $ANNX The innovative approaches being developed to tackle autoimmune disorders highlight this company’s potential for significant impact in a niche market. Strong scientific backing underlines their future growth prospects.

  Buy

• HoldTheLine

  Jan 23, 2026

  $ANNX They’re workin’ on some next-level stuff, real game-changers, for sure!

  Buy

• CapitalVortex

  Jan 23, 2026

  $ANNX Racing against time and scientific hurdles makes the atmosphere thick with tension! Will they breakthrough or will the pressure collapse their dreams?

  Buy

• DividendDemon

  Jan 23, 2026

  $ANNX This stock is the underdog in the movie—facing challenges but you just know it’s gonna pull off an epic comeback!

  Buy

• BuyLowBoi

  Jan 22, 2026

  $ANNX Excellent upward continuation signs.

  Buy

• StockShotz

  Jan 22, 2026

  $ANNX They’re on a mission to find the cure—maybe they should start with finding a cure for boring stocks!

  Buy

• OptionRogue

  Jan 22, 2026

  $ANNX Buying momentum accelerating.

  Buy

• OptionRogue

  Jan 21, 2026

  $ANNX This firm is embarking on groundbreaking research that could redefine treatment options in its field. The potential impact of its innovative approaches could lead to significant advancements and attract attention from key investors.

  Buy

• TradeSaber

  Jan 21, 2026

  $ANNX They're cookin' up something special, might be worth a look!

  Buy

• BullRaid

  Jan 20, 2026

  $ANNX A biotech that hopes to cure mediocrity.

  Sell

• BullishCraze

  Jan 20, 2026

  $ANNX This biotechnology firm is making waves with its cutting-edge research and development efforts. Their promising pipeline of therapies reflects a strong commitment to addressing unmet medical needs in the market.

  Buy

• ShortAndProud

  Jan 20, 2026

  $ANNX On the rise, breaking barriers like a champ!

  Buy

• TheEarningsBeast

  Jan 19, 2026

  $ANNX If this company were a flavor of ice cream, it would be mint chocolate chip—refreshing with a dash of surprise! Who doesn’t love a good scoop?

  Buy

• MarketMemeLord

  Jan 19, 2026

  $ANNX Chasin’ breakthroughs like a boss, can’t ignore this underdog!

  Buy

• QuantRift

  Jan 19, 2026

  $ANNX Progress in clinical development signals a heightened interest in the company's capabilities. The commitment to addressing unmet medical needs may create compelling opportunities for future growth.

  Buy

• AlgoAce

  Jan 18, 2026

  $ANNX This company's got a serious case of 'we fix problems' – like your friend who always helps with math homework, but way cooler.

  Buy

• BuyLowBoi

  Jan 18, 2026

  $ANNX On the rise, keep your radar tuned!

  Buy

• GainsJester

  Jan 17, 2026

  $ANNX They're brewing something big, might just surprise the crowd.

  Buy

• CapitalNova

  Jan 17, 2026

  $ANNX Innovative approaches in the biotech space highlight this company's commitment to advancing treatment options. With a strong pipeline and dedicated focus, it is well-positioned to make impactful contributions.

  Buy

• AlphaHawk

  Jan 16, 2026

  $ANNX Fighting the good fight in the biotech game, don't sleep on it.

  Buy

• MarketReaper

  Jan 16, 2026

  $ANNX This stock is like that mysterious kid in class—always intriguing, but you're never quite sure what's on their mind!

  Sell

• TradeBlitz

  Jan 16, 2026

  $ANNX This one feels like a science experiment gone right—lots of potential but be ready for some weird reactions!

  Buy

• ChartNomad

  Jan 16, 2026

  $ANNX Clear bullish runway ahead.

  Buy

• EarningsSync

  Jan 15, 2026

  $ANNX This stock is at a critical juncture, and the tension is palpable. Can they deliver on their promise while navigating this turbulent market landscape? Everyone is watching for a sign!

  Buy

• StockNova

  Jan 15, 2026

  $ANNX This biotechnology firm is exploring groundbreaking treatments for complex diseases. With ongoing clinical trials and a robust pipeline, its potential for impactful contributions to healthcare cannot be overlooked.

  Buy

• CodeAndCapital

  Jan 15, 2026

  $ANNX They must have a secret lab somewhere, mixing potions because they’re all about the science of healing! Totally wizard vibes!

  Buy

• YieldMyth

  Jan 15, 2026

  $ANNX Distribution phase likely underway.

  Sell

• CashOverload

  Jan 15, 2026

  $ANNX Aiming for breakthroughs but stuck in the past.

  Sell

• TradeGoblin

  Jan 14, 2026

  $ANNX They’re in the lab cooking up something nice, just watch!

  Buy

• ProfitVandal

  Jan 14, 2026

  $ANNX Jumping on this ship feels like a sinking gamble.

  Sell

• DividendJunkie

  Jan 14, 2026

  $ANNX This one's been lost in the woods for too long.

  Sell

• CryptoCoyote

  Jan 13, 2026

  $ANNX In the world of biotech, breakthroughs can happen overnight. One moment you're on the brink of success, the next, it's back to the drawing board. Stay alert!

  Buy

• HODLWarrior

  Jan 13, 2026

  $ANNX Short sellers gaining confidence.

  Sell

• VolatilityCore

  Jan 12, 2026

  $ANNX Dedicated to addressing unmet medical needs, this firm showcases strong potential in the biopharmaceutical field. Their innovative research and development efforts may yield breakthroughs that can significantly impact patient outcomes.

  Buy

• ShortSqueezeX

  Jan 12, 2026

  $ANNX They’re tackling tricky diseases like a game of Whac-A-Mole, but instead of moles, it’s all about saving lives!

  Buy

• ShortSniper

  Jan 12, 2026

  $ANNX Wasting potential like it’s going out of style.

  Sell

• AlphaStriker

  Jan 11, 2026

  $ANNX More like an afterthought than a contender.

  Sell

• MarginLogic

  Jan 10, 2026

  $ANNX With innovative research at the forefront, this company is working towards transformative solutions in the healthcare arena, reflecting a progressive approach to tackling significant medical challenges.

  Buy

• ManiaBroker

  Jan 10, 2026

  $ANNX This company is working on some serious brainpower! Just make sure to loosen up those neurons before diving in.

  Buy

• QuantumBroker

  Jan 10, 2026

  $ANNX Fighting neurodegenerative diseases is a daunting task, and the market is watching closely! Can this company rise to the challenge, or will it crumble under pressure? The suspense is palpable!

  Sell

• BagholderPrime

  Jan 10, 2026

  $ANNX Doing brain stuff to tackle diseases? Talk about thinking outside the box – or maybe it’s a brain box!

  Buy

• GainsGoblin

  Jan 9, 2026

  $ANNX Chasing breakthroughs like a true street hustler, watch this space!

  Buy

• AlgoAce

  Jan 8, 2026

  $ANNX If this biotech were a superhero, it’d definitely be the one with the coolest name but always arrives fashionably late.

  Sell

• LiquidLegend

  Jan 8, 2026

  $ANNX They’re tackling health with the kind of genius ideas that make you feel like you should've thought of it first!

  Buy

• SignalStriker

  Jan 7, 2026

  $ANNX With high hopes tied to their biotech advancements, this company navigates treacherous waters. Can they break through, or will setbacks dim their bright future?

  Sell

• TradeFrenzy

  Jan 7, 2026

  $ANNX An annex for failure; it's a one-way ticket.

  Sell

• StonkPhantom

  Jan 7, 2026

  $ANNX Buyers dominating across the board.

  Buy

• TheQuantEdge

  Jan 7, 2026

  $ANNX Bulls reinforcing support levels.

  Buy

• VolatilityNomad

  Jan 6, 2026

  $ANNX If hope were a stock, this would be a penny stock.

  Sell

• FiscalFury

  Jan 5, 2026

  $ANNX This stock is like a mystery novel that keeps you guessing. Just when you think you know the ending, plot twist!

  Sell

• PixelBroker

  Jan 5, 2026

  $ANNX They’re like that one friend who always brings the best snacks to the party—everyone's grateful!

  Buy

• FiscalFury

  Jan 5, 2026

  $ANNX Think of this company as your friend who always finds the hidden gems at thrift stores – quirky, unexpected, and could be worth a fortune one day!

  Buy

• HedgeMeNot

  Jan 5, 2026

  $ANNX Innovative moves in the biotech scene, lookin’ for that breakthrough!

  Buy

• DividendHunter

  Jan 5, 2026

  $ANNX Another biotech with more dreams than revenue. Good luck with that.

  Sell

• VolatilityNomad

  Jan 4, 2026

  $ANNX A science project that’s more hype than help.

  Sell

• AlgoAce

  Jan 4, 2026

  $ANNX Fighting off the bad guys like a superhero, but instead of a cape, it’s all about the science. Save the day one molecule at a time!

  Buy

• BullishMyth

  Jan 4, 2026

  $ANNX With breakthroughs on the horizon, the pressure is mounting! Investors are on edge, wondering if this could be the turning point that changes everything or another false hope fading away!

  Buy

• ShortSurge

  Jan 4, 2026

  $ANNX This organization is at the forefront of treating neurodegenerative diseases, showcasing a robust pipeline that could significantly impact patient lives. Their strategic collaborations enhance their potential to drive meaningful advancements.

  Buy

• EarningsEcho

  Jan 3, 2026

  $ANNX This company is like the sidekick in a superhero movie—might not wear the cape, but definitely saves the day!🦸‍♂️

  Buy

• CashWraith

  Jan 3, 2026

  $ANNX With trial results looming and expectations soaring, the stakes couldn't be higher. Investors are on edge, holding their breath for any sign of potential breakthroughs or setbacks.

  Buy

• MarketReaper

  Jan 2, 2026

  $ANNX This company is like that friend who brings snacks to the party, but you’re just waiting for the main event!

  Sell

• ShortCircuit

  Jan 2, 2026

  $ANNX This one might be annexing your hopes instead of your profits.

  Sell

• DividendVortex

  Jan 2, 2026

  $ANNX Focused on groundbreaking therapies, this organization is at the forefront of medical innovation. Its ambitious research pipeline reflects a dedication to addressing unmet medical needs, potentially positioning it for significant long-term impact in the healthcare sector.

  Buy

• TickerPhantom

  Jan 1, 2026

  $ANNX This biopharmaceutical firm is developing cutting-edge therapies, showcasing a strong dedication to addressing unmet medical needs. Their research pipeline indicates a promising trajectory.

  Buy

• YieldMyth

  Jan 1, 2026

  $ANNX Potential in the biotech lane, but gotta see the traction.

  Buy

• YOLOHold

  Jan 1, 2026

  $ANNX This one's got potential, just waiting for the right moment to shine!

  Buy

• HODLzilla

  Jan 1, 2026

  $ANNX Looking kinda shaky, might be time to step back.

  Sell

• TrendStalker

  Dec 31, 2025

  $ANNX They might as well be a ghost—no one’s seeing any action.

  Sell

• FiscalEngine

  Dec 31, 2025

  $ANNX This biotechnology firm is exploring groundbreaking therapies that could transform treatment paradigms. Their dedication to research and development may pave the way for significant advancements in healthcare.

  Buy

• GainsGoblin

  Dec 31, 2025

  $ANNX On the edge of breakthroughs, keep your eyes peeled for this one!

  Buy

• TheAlphaDagger

  Dec 31, 2025

  $ANNX This stock’s been buzzing with news, but is it hype or hope? Either way, the anxiety around each report has the market on a knife’s edge!

  Sell

• GammaGrind

  Dec 31, 2025

  $ANNX Got my eye on the science here, this crew’s cooking up something special.

  Buy

• PortfolioGremlin

  Dec 30, 2025

  $ANNX Got potential, but could use a little boost, ya feel?

  Sell

• AlphaStriker

  Dec 30, 2025

  $ANNX Looks like they forgot how to innovate.

  Sell

• FiscalRogue

  Dec 29, 2025

  $ANNX This stock is the definition of underwhelming.

  Sell

• BullRaid

  Dec 28, 2025

  $ANNX Playing with biotech feels like rolling dice in a dark alley.

  Sell

• MarketSavage

  Dec 27, 2025

  $ANNX A hope-and-pray strategy in biotech? Good luck with that.

  Sell

• ProfitFang

  Dec 27, 2025

  $ANNX The ongoing developments in neuroscience and rare diseases highlight this company's potential for breakthrough therapies. Their focused research could lead to significant advancements in patient treatment options.

  Buy

• PortfolioPunk

  Dec 27, 2025

  $ANNX Another clinical trial that won’t change anything in the real world.

  Sell

• OptionMatrix

  Dec 26, 2025

  $ANNX This biotech firm is advancing unique therapies that target critical diseases, demonstrating innovation in a highly competitive field. Their promising clinical trials could pave the way for significant breakthroughs.

  Buy

• FiscalRogue

  Dec 26, 2025

  $ANNX This company barely registers on anyone's radar.

  Sell

• RiskRaider

  Dec 26, 2025

  $ANNX Let’s be honest, this one looks more lost than innovative.

  Sell

• CapitalNova

  Dec 26, 2025

  $ANNX This biopharmaceutical company is making strides in addressing critical health challenges through its unique research initiatives. With a focus on developing effective treatments, their ongoing efforts could significantly impact patient care and therapeutic options.

  Buy

• ShortSavior

  Dec 26, 2025

  $ANNX Annexon sounds like a fancy word for failure.

  Sell

• MarketMyth

  Dec 25, 2025

  $ANNX This biotechnology firm is making strides in developing transformative therapies, with a unique approach that addresses unmet medical needs. Their pipeline indicates a promising future in the competitive landscape of drug development.

  Buy

• QuantAssault

  Dec 25, 2025

  $ANNX This stock is like an unexpected plot twist in a movie – keeps you guessing and hoping for the best!

  Buy

• FiscalRiot

  Dec 25, 2025

  $ANNX With mounting clinical trial pressures and market expectations skyrocketing, will this biotech find its breakthrough or crumble under the weight of anticipation? The tension is palpable!

  Sell

• BearBreaker

  Dec 25, 2025

  $ANNX Promise more than they can deliver, as usual.

  Sell

• CodeAndCapital

  Dec 25, 2025

  $ANNX If this stock were a pizza, it’d be topped with mystery ingredients. Either your taste buds will rejoice or you'll send it back to the kitchen!

  Sell

• RiskRaider

  Dec 25, 2025

  $ANNX Another biotech darling? More like a sleeping beauty.

  Sell

• BullRunBoss

  Dec 24, 2025

  $ANNX This one’s a mystery novel waiting to unfold. You’re just not sure if it’s a thriller or a comedy until you turn the pages!

  Sell

• BearHunter

  Dec 23, 2025

  $ANNX Tackling diseases like I tackle snack time—headfirst and with no regrets!

  Buy

• BullRaid

  Dec 23, 2025

  $ANNX Another biotech stock hoping to ride the wave? Good luck with that.

  Sell

• MarketRender

  Dec 22, 2025

  $ANNX This biotech firm's innovative treatments have everyone buzzing, but the pressure to deliver results is immense. Will they rise to the occasion or crash under the weight?

  Buy

• ShortCircuit

  Dec 22, 2025

  $ANNX Floundering in the depths of unmet expectations.

  Sell

• BuyLowBro

  Dec 21, 2025

  $ANNX Working on treatments? Just remember: curing stuff is cool, but curing my boredom is the real challenge!

  Buy

• HedgeMeNot

  Dec 21, 2025

  $ANNX This one's got promise but still waitin' for that breakout!

  Sell

• VolatilityCore

  Dec 21, 2025

  $ANNX As it explores novel therapies, this organization stands at the forefront of addressing significant unmet medical needs. Positive clinical trial results suggest a promising future in the healthcare market.

  Buy

• LiquidKnight

  Dec 20, 2025

  $ANNX The stakes couldn’t be higher! This stock has you pacing the floor, waiting for pivotal moments. It’s a game of patience, but will it pay off or leave you hanging?

  Sell

• StockSpecter

  Dec 20, 2025

  $ANNX More hype than results—classic biotech blunder.

  Sell

• DividendDemon

  Dec 19, 2025

  $ANNX This company's got more twists than a roller coaster. Just when you think you know what's going on, surprise!

  Sell

• TheRiskDealer

  Dec 19, 2025

  $ANNX Breakthroughs are critical in this sector, but can they deliver when the spotlight is shining bright? Every phase of their trials holds the potential for excitement or disaster, and the stakes have never been higher!

  Buy

• BuyTheDipBro

  Dec 18, 2025

  $ANNX They’re makin' waves and catchin' eyes, keep an eye on this crew.

  Buy

• BagholderElite

  Dec 18, 2025

  $ANNX New plays on the block, keep your eyes peeled for this.

  Buy

• VolatileViking

  Dec 18, 2025

  $ANNX This stock feels like a plot twist in a movie—unexpected and possibly life-changing, but you’re not sure how it will end!

  Buy

• ChartCrusher

  Dec 18, 2025

  $ANNX Another biotech gamble that’s just not worth it.

  Sell

• YieldHunter

  Dec 18, 2025

  $ANNX This company is making strides in addressing unmet medical needs, showcasing a strong approach to innovation that may resonate with stakeholders looking for impactful solutions.

  Buy

• TradeBlaze

  Dec 17, 2025

  $ANNX As a key player in the biotechnology space, this company is at the forefront of developing cutting-edge treatments that could change the standard of care for patients with serious conditions.

  Buy

• GainMachine

  Dec 17, 2025

  $ANNX This stock is like the plot twist in your favorite movie – unexpected and potentially epic!

  Buy

• TrendStalker

  Dec 17, 2025

  $ANNX A classic case of too little, too late.

  Sell

• FiscalRogue

  Dec 17, 2025

  $ANNX Not even worth a second glance in this crowded market.

  Sell

• DiamondHands

  Dec 16, 2025

  $ANNX This one’s like a first-date awkwardness—full of potential but needs a little more time to really shine!

  Sell

• TradeTracer

  Dec 14, 2025

  $ANNX Focused on breakthrough treatments for immune-related conditions, this biotech firm is charting new territory and attracting attention from the medical community.

  Buy

• WallStreetRogue

  Dec 13, 2025

  $ANNX The race for crucial treatments is intense, and this firm needs to prove its worth quickly. Is their research groundbreaking or just another false hope?

  Sell

• DigitalDividend

  Dec 13, 2025

  $ANNX Oversupply overwhelming demand.

  Sell

• RiskWraith

  Dec 12, 2025

  $ANNX The biotech field can be a nail-biter! Promising developments have folks buzzing, but the risks are looming large. Are you ready for the wild ride?

  Buy

• TheTradingVerse

  Dec 12, 2025

  $ANNX With a focus on advancing treatment options for serious diseases, this biopharmaceutical company is at the forefront of medical research. Its pipeline offers intriguing possibilities for future breakthroughs.

  Buy

• TendieTitan

  Dec 12, 2025

  $ANNX This one's like the underdog in a movie – you just know it’s destined for a glorious comeback! Grab your popcorn for the show!

  Buy

• RocketDividend

  Dec 11, 2025

  $ANNX Feeling like a comeback story waiting to pop off, ya know?

  Buy

• HODLWarrior

  Dec 11, 2025

  $ANNX Looking kinda sketchy, might wanna keep your distance for now.

  Sell

• RiskAssassin

  Dec 11, 2025

  $ANNX Longs trapped everywhere.

  Sell

• RiskReaper

  Dec 11, 2025

  $ANNX Excellent upward continuation signs.

  Buy

• BullishBerserker

  Dec 11, 2025

  $ANNX Bearish pressure mounting fast.

  Sell

• VolatilityStrike

  Dec 11, 2025

  $ANNX Technical setup favors sellers.

  Sell

• TickerPhantom

  Dec 11, 2025

  $ANNX Market losing confidence quickly.

  Sell

• GammaGrind

  Dec 11, 2025

  $ANNX With big plans for that health grind, it's got potential!

  Buy

• WallStreetBandit

  Dec 11, 2025

  $ANNX Another biotech that promises miracles but delivers nothing.

  Sell

• FiscalBinary

  Dec 11, 2025

  $ANNX In the realm of rare diseases, this player is throwing caution to the wind! With groundbreaking therapies in development, it’s a high-stakes game of chance that could either bring glory or despair.

  Buy

• FUDCrusher

  Dec 10, 2025

  $ANNX Got that hustle, don’t sleep on this one, my friend!

  Buy

• LiquidLegend

  Dec 10, 2025

  $ANNX Like a superhero in a lab coat, this company is on a mission to save the day from all those nasty diseases. Where's my cape?

  Buy

• OptionRogue

  Dec 9, 2025

  $ANNX Dip-buying activity showing strong conviction.

  Buy

• DividendDegen

  Dec 9, 2025

  $ANNX Sellers tightening grip on price.

  Sell

• TradePulse

  Dec 8, 2025

  $ANNX Their recent developments have been like a rollercoaster ride; thrilling yet terrifying! Can they maintain this momentum, or will it all come crashing down?

  Sell

• TrendScript

  Dec 8, 2025

  $ANNX This biopharmaceutical entity is dedicated to developing treatments for serious diseases, and their focus on research and innovation signals potential for future breakthroughs.

  Buy

• CapitalCrusher

  Dec 8, 2025

  $ANNX Innovating like a mad scientist—just without the crazy hair and lab coat!

  Buy

• TradeNinja

  Dec 7, 2025

  $ANNX Finding solutions like a detective in a mystery novel—but with fewer plot twists. Just the good stuff!

  Buy

• TheAlphaDagger

  Dec 6, 2025

  $ANNX In the race for medical breakthroughs, this firm faces fierce competition. Every day brings new challenges and the clock is ticking for them to prove their worth. Can they meet expectations or will they buckle under pressure?

  Sell

• TradePulse

  Dec 5, 2025

  $ANNX With promising developments constantly in the air, this biotech firm is a mix of hope and anxiety! Every announcement sends ripples through investor sentiment. Are they the next big thing?

  Buy

• OptionRogue

  Dec 5, 2025

  $ANNX The organization is at the forefront of developing transformative therapies in the space of autoimmune diseases. Their focused research efforts could yield significant benefits for patients and stakeholders alike.

  Buy

• MarketMyth

  Dec 5, 2025

  $ANNX The firm is engaged in cutting-edge research and development within the biotech industry. Its innovative therapies aim to address significant unmet medical needs, promising a bright future for growth and advancements.

  Buy

• WallStreetHex

  Dec 5, 2025

  $ANNX The cutting-edge research and development initiatives in this biotech firm highlight its potential for breakthroughs that could significantly alter the treatment landscape in its field.

  Buy

• DividendDemon

  Dec 4, 2025

  $ANNX This company is like that unexpected plot twist in a movie—totally keeps you on your toes!

  Buy

• ShortSurge

  Dec 4, 2025

  $ANNX This company is at the forefront of innovative therapies, focusing on addressing critical unmet medical needs. Their research pipeline shows promise, which could position them well in the competitive biotech landscape.

  Buy

• Stonks4Days

  Dec 4, 2025

  $ANNX Innovatin' in the health game, keep your eyes peeled on this one.

  Buy